Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 197

1.

Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer.

Li J, Rugo HS.

Breast Dis. 2011;33(2):83-92. doi: 10.3233/BD-2010-0326. Review.

PMID:
22142661
2.

Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature.

Gnant M, Clézardin P.

Cancer Treat Rev. 2012 Aug;38(5):407-15. doi: 10.1016/j.ctrv.2011.09.003. Epub 2011 Oct 7. Review.

PMID:
21983264
3.

Anticancer activity of bisphosphonates in breast cancer.

Gnant M.

Anticancer Agents Med Chem. 2012 Feb;12(2):114-22. Review.

PMID:
21864231
4.

Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients.

Solomayer EF, Gebauer G, Hirnle P, Janni W, Lück HJ, Becker S, Huober J, Krämer B, Wackwitz B, Wallwiener D, Fehm T.

Ann Oncol. 2012 Sep;23(9):2271-7. doi: 10.1093/annonc/mdr612. Epub 2012 Mar 1.

5.

Bisphosphonates and breast cancer prevention.

Chlebowski RT, Col N.

Anticancer Agents Med Chem. 2012 Feb;12(2):144-50. Review.

PMID:
21864227
6.

Intravenous bisphosphonates for breast cancer: impact on patient outcomes and scientific concepts.

Gnant M.

Breast Dis. 2011;33(2):71-81. doi: 10.3233/BD-2010-0325. Review.

PMID:
22142663
7.

Bisphosphonates as treatment of bone metastases.

Holen I, Coleman RE.

Curr Pharm Des. 2010;16(11):1262-71. Review.

PMID:
20166976
8.

Zoledronic acid - a multiplicity of anti-cancer action.

Yuasa T, Kimura S, Ashihara E, Habuchi T, Maekawa T.

Curr Med Chem. 2007;14(20):2126-35. Review.

PMID:
17691952
9.

Bisphosphonates in breast cancer: clinical activity and implications of preclinical data.

Aft R.

Clin Adv Hematol Oncol. 2011 Mar;9(3):194-205. Review.

PMID:
21475125
10.

Bisphosphonates for cancer patients: why, how, and when?

Body JJ, Mancini I.

Support Care Cancer. 2002 Jul;10(5):399-407. Epub 2001 Oct 19. Review.

PMID:
12136223
11.

Bisphosphonates as anticancer therapy for early breast cancer.

Mahtani R, Jahanzeb M.

Clin Breast Cancer. 2010 Oct 1;10(5):359-66. doi: 10.3816/CBC.2010.n.047. Review.

PMID:
20920980
12.

Effects of bone-targeted agents on cancer progression and mortality.

Coleman R, Gnant M, Morgan G, Clezardin P.

J Natl Cancer Inst. 2012 Jul 18;104(14):1059-67. doi: 10.1093/jnci/djs263. Epub 2012 Jul 2. Review.

13.

New results from the use of bisphosphonates in cancer patients.

Coleman R, Gnant M.

Curr Opin Support Palliat Care. 2009 Sep;3(3):213-8. doi: 10.1097/SPC.0b013e32832f4149. Review.

PMID:
19561507
14.

The role of bisphosphonates in breast and prostate cancers.

Brown JE, Neville-Webbe H, Coleman RE.

Endocr Relat Cancer. 2004 Jun;11(2):207-24. Review.

15.

Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer.

Coleman R.

Clin Breast Cancer. 2007 Jul;7 Suppl 1:S29-35. Review.

PMID:
17683651
16.

Should bisphosphonates be utilized in the adjuvant setting for breast cancer?

Lipton A.

Breast Cancer Res Treat. 2010 Aug;122(3):627-36. doi: 10.1007/s10549-010-0935-7. Epub 2010 May 21. Review.

PMID:
20490653
17.

Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease.

Neville-Webbe HL, Coleman RE.

Eur J Cancer. 2010 May;46(7):1211-22. doi: 10.1016/j.ejca.2010.02.041. Epub 2010 Mar 27. Review.

PMID:
20347292
18.
19.

Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.

Ibrahim A, Scher N, Williams G, Sridhara R, Li N, Chen G, Leighton J, Booth B, Gobburu JV, Rahman A, Hsieh Y, Wood R, Vause D, Pazdur R.

Clin Cancer Res. 2003 Jul;9(7):2394-9.

20.

New role for an established drug? Bisphosphonates as potential anticancer agents.

Koul HK, Koul S, Meacham RB.

Prostate Cancer Prostatic Dis. 2012 Jun;15(2):111-9. doi: 10.1038/pcan.2011.41. Epub 2011 Aug 30. Review.

PMID:
21876554
Items per page

Supplemental Content

Write to the Help Desk